Skip to main content

Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Buy Article:

Your trusted access to this article has expired.

$63.00 plus tax (Refund Policy)

Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: CAAX binding site; CCI-779; STAT3 tyrosine phosphorylation; Tipifarnib; haematological malignancies; mTOR Kinase pathway

Document Type: Research Article

Affiliations: Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Publication date: 2006-12-01

More about this publication?
  • Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more